Lipella Pharmaceuticals, Inc. · OTC:LIPO

Lipella Pharmaceuticals — H.C. Wainwright 26th Annual Global Investment Conference (September 2024)

21 slides from Lipella Pharmaceuticals's conference presentation, September 2024

  1. Slide 1: A Clinical Stage Biotechnology Company Addressing Serious Diseases with Significant Unmet Need

    A Clinical Stage Biotechnology Company Addressing Serious Diseases with Significant Unmet Need H.C. Wainwright 26th Annual Global Investment Conference Jonathan Kaufman Dr. Michael Chancellor CEO and Co-founder CMO and Co-founder NASDAQ:LIPO lipellapharmaceuticals.com

  2. Slide 2: Disclaimers

    NASDAQ:LIPO DISCLAIMERS The information in this presentation is being provided so you can familiarize yourself with Lipella Pharmaceuticals Inc. (“Lipella,” the “Company,” “we,” “us,” or “our”) during this informational meeting. We request that you keep any information we provide at this meeting con

  3. Slide 3: About / Market Data

    NASDAQ:LIPO ABOUT MARKET DATA Lipella Pharmaceuticals is a clinical-stage biotechnology company developing and SYMBOL NASDAQ: LIPO commercializing treatments for serious diseases. Price as of 8-19-2024 $0.41 Our proprietary drug delivery technology has 52 Week Range $0.36 - $2.71 potential applicati

  4. Slide 4: Business Growth Strategy

    NASDAQ:LIPO BUSINESS GROWTH STRATEGY Focused on rare and orphan drug indications, Lipella is leveraging the 505(b)(2) pathway. This strategy is expected to lower cost and expedite the approval process. Why rare and orphan drugs? Why leverage the 505(b)(2) pathway? • Lipella can be first to market by

  5. Slide 5: Investment Highlights

    NASDAQ:LIPO INVESTMENT HIGHLIGHTS Attractive Market: Targeting two patient populations with significant unmet needs and no current FDA approved drug treatments. Compelling Pipeline: Two IND-approved lead assets in phase 2 clinical trials, both 505(b)(2) drug candidates: • LP-10, a bladder intravesic

  6. Slide 6: De-risked Lead Programs with Robust Revenue Opportunity

    NASDAQ:LIPO DE-RISKED LEAD PROGRAMS WITH ROBUST REVENUE OPPORTUNITY 505(b)(2) drug candidates Positioned For Market Exclusivity LP-10 Liposomal tacrolimus for the treatment of • Hemorrhagic cystitis affects ~60,000 annually Hemorrhagic cystitis. LP-10 has a well- established mechanism of action and

  7. Slide 7: Differentiated Technology Platform: Liposomal Formulation of Tacrolimus

    NASDAQ:LIPO DIFFERENTIATED TECHNOLOGY PLATFORM: Liposomal Formulation of Tacrolimus Maximizing Therapeutic Responses with Directed Localized Administration Optimized Efficacy By encapsulating tacrolimus in liposomes, our technology ensures a more stable and controlled release, maximizing therapeutic

  8. Slide 8: Near Term Catalysts

    NASDAQ:LIPO NEAR TERM CATALYSTS Upcoming Proprietary Asset Pre-clinical IND-Enabling Phase 1 Phase 2 Phase 3 Milestones Anticipate FPI in 2H 2024, LP-10 Hemorrhagic Cystitis Study Completion in 2025 First 2 patients dosed, LP-310 Oral Lichen Planus Data by YE 2024 H2 2024 H1 2025 H2 2025 • Patients

  9. Slide 9: Hemorrhagic Cystitis, Uncontrolled Urinary Blood Loss

    NASDAQ:LIPO HEMORRHAGIC CYSTITIS, UNCONTROLLED URINARY BLOOD LOSS Hemorrhagic cystitis is a serious, life-threatening bladder damage from pelvic radiation therapy and/or bladder-toxic chemotherapy. Millions of patients are 20% of these patients An increasing US Years after receiving Hemorrhagic cyst

  10. Slide 10: LP-10 for Hemorrhagic Cystitis (HC)

    NASDAQ:LIPO LP-10 FOR HEMORRHAGIC CYSTITIS (HC) Liposomal tacrolimus treatment for hemorrhagic cystitis • Potent vasoconstrictor; reduces Urgent Need For Effective HC Treatment Options capillary blood flow to the bladder lumen • HC is challenging to treat due to poor blood flow • Potent anti-inflamm

  11. Slide 11: LP-10: Phase 2a Trial

    NASDAQ:LIPO LP-10: PHASE 2A TRIAL A Phase 2a clinical trial Top line results Next Steps (NCT01393223): • Multi-center, dose- • All subjects tolerated LP-10 • Initiate Phase 2b trial in escalation study instillations with no serious adverse LP-10 in 1H 2025 • 13 subjects with events (SAE) reported mo

  12. Slide 12: Oral Lichen Planus (OLP)

    NASDAQ:LIPO ORAL LICHEN PLANUS (OLP) OLP is a chronic inflammatory, T-cell-mediated There is no current pharmacotherapy for oral lichen planus autoimmune oral mucosal disease Current OLP Treatments: Palliative with Significant Side Effects • Complications: Pain, weight loss, stress, depression, scar

  13. Slide 13: LP-310 (liposomal-tacrolimus) for Oral Lichen Planus

    NASDAQ:LIPO • Similar formulation of LP-10 for oral rinse LP-310 (liposomal-tacrolimus) for • Increased local concentration in oral cavity while minimalizing systemic toxicity • High safety profile with no systemic toxicity Oral Lichen Planus observed • Low COGS and fast development plan • LP-310 pr

  14. Slide 14: LP-310 Clinical Snapshot

    NASDAQ:LIPO LP-310 CLINICAL SNAPSHOT Design : Randomized, prospective multicenter dose escalation study with 24 patients. Efficacy : Anticipate a statistically significant decrease in oral lichen planus lesion score within 1 week of administration, maintained for at least 4 weeks. Quality of Life :

  15. Slide 15: Asset Pipeline

    NASDAQ:LIPO ASSET PIPELINE A growing pipeline with strong patent protection Upcoming Proprietary Asset Pre-clinical IND-Enabling Phase 1 Phase 2 Phase 3 Milestones LP-10 Anticipate phase 2b trial to hemorrhagic cystitis start in 1H 2025 LP-310 First 2 patients dosed, oral lichen planus Topline data

  16. Slide 16: LP-410 for Oral Graft-Versus-Host Disease

    NASDAQ:LIPO LP-410 FOR ORAL GRAFT-VERSUS-HOST DISEASE Oral Graft-Versus-Host Disease (GVHD) is a clinical syndrome where donor-derived immunocompetent T cells react against patient tissues directly or through exaggerated inflammatory responses following HCT. • GVHD is a major cause of morbidity and

  17. Slide 17: LP-50 for Bladder Cancer

    NASDAQ:LIPO LP-50 FOR BLADDER CANCER Novel liposomal formulation of checkpoint inhibitors • Intravesical formulation for local, intravesical PD-1 (i.e. checkpoint) inhibition, intended for the treatment of non-muscle invasive bladder cancer (NMIBC). • Intravesical immunotherapy presents a promising

  18. Slide 18: Manufacturing Capabilities

    NASDAQ:LIPO MANUFACTURING CAPABILITIES • Lipella maintains a sterile manufacturing facility in Pittsburgh, PA for the production of clinical supplies and research products. • LP-10 has been produced at high quantities in this facility for Lipella's clinical trials. • The facility is also used for de

  19. Slide 19: Experienced Management Team

    NASDAQ:LIPO EXPERIENCED MANAGEMENT TEAM Jonathan Kaufman, PhD Michael Chancellor, MD Doug Johnston, CPA Chief Financial Officer Chief Executive Officer Chief Medical Officer • 15+ Years Experience • 23+ Years Experience • 30+ Years Experience • Jointed Lipella in 2021 • Co-founded Lipella in 2005 •

  20. Slide 20: Key Takeaways

    NASDAQ:LIPO KEY TAKEAWAYS • Broad portfolio of three promising IND-approved • Targeting multiple patient populations including: assets. • ~60,000 new diagnoses of hemorrhagic cystitis each year. • LP-10 and LP-410 granted FDA Orphan Drug Designation; positioned for multiple accelerated • 6 million p

  21. Slide 21: A Clinical Stage Biotechnology Company Addressing Serious Diseases

    A Clinical Stage Biotechnology Company Addressing Serious Diseases with NASDAQ:LIPO Significant Unmet Need Lipella Pharmaceuticals Inc. 7800 Susquehanna Street, Suite 505 Pittsburgh, PA 15208 412-894-1853 lipellapharmaceuticals.com

Lipella Pharmaceuticals — H.C. Wainwright 26th Annual Global Investment Conference (September 2024) on 6ix